BioHealth News Archive
Pitch Perfect: The Art and Science of Communicating with Investors
Pitch Perfect: The Art and Science of Communicating with Investors Before AND After Funding Communicating with investors before AND after funding is both an…
Read More
AstraZeneca Gears Up to Vaccinate the World Against Covid-19 – WSJ
Among the front-runners racing to deliver a Covid-19 shot, AstraZeneca PLC has the least vaccine experience. But it has promised the world the most…
Read More
BioInnovation Institute takes in new cohort of promising early-stage innovations – PharmiWeb.com
Seven start-up companies and university research projects across a range of therapeutic areas and geographical locations form latest intake for life science incubator BioInnovation…
Read More
NEA Welcomes Scott Gottlieb, M.D., as Special Partner | NEA | New Enterprise Associates
Chevy Chase, MD – May 22, 2019 – New Enterprise Associates, Inc. (NEA), a leading global venture capital firm, today announced the appointment of…
Read More
BRAINBox Solutions Announces First Close in $23 Million in Series A Financing to Support Development and Pivotal Clinical Trial of ‘Breakthrough’ Concussion Diagnostic/Prognostic Test
Scott Gazelle, MD, PhD, MPH, FACR Appointed to Board of Directors and Damon Kuehl, MD, FACEP Joins Scientific Advisory Board RICHMOND, Va. (December 8,…
Read More
TEDCO’s Entrepreneur Expo 2019 – Recap | TEDCO
TEDCO's 2019 Entrepreneur Expo took place on October 29, 2019, at The Hotel At The University of Maryland! See what Maryland has to offer…
Read More
QIAGEN to launch QuantiFERON SARS-CoV-2 for research into causes, spread and control of COVID-19 through T-cell response
Hilden, Germany and Germantown, Maryland, December 7, 2020 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the launch of its QuantiFERON…
Read MoreMacroGenics strikes commercialization deal with Eversana ahead of potential Food and Drug Administration approval for breast cancer treatment – Washington Business Journal
The agency's decision is expected to drop Dec. 18. Image: MacroGenics is led by CEO and co-founder Scott Koenig. JOANNE S. LAWTON {iframe}https://www.bizjournals.com/washington/news/2020/12/03/macrogenics-locks-in-commercialization-deal-ahead.html{/iframe}
Read More
Doudna Talks Nobel Success and Women in Science
Jennifer Doudna PhD, the UC Berkeley biochemist who shared the 2020 Nobel Prize in Chemistry with Emmanuelle Charpentier PhD, was the recent guest of…
Read More
BioHealth Crystal Ball on Vimeo
Join Rich Bendis, Pete Briskman and Ann Rutledge as they Discuss Securitization, Covid-19 and Political Analysis related to the BioHealth industry. {iframe}https://vimeo.com/486175068/1f9edf7d87{/iframe}
Read More
Novavax Announces COVID-19 Vaccine Clinical Development Progress | Novavax Inc. – IR Site
GAITHERSBURG, Md., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided…
Read More
Johns Hopkins study shows ‘magic mushrooms’ may be effective in treating major depression – Baltimore Business Journal
Four weeks after receiving monitored doses of psilocybin, researchers reported more than half of the study's 24 participants had achieved remission from their depression.…
Read More
AstraZeneca’s COVID-19 vaccine, up to 90% effective in late-stage trials, is being manufactured in Baltimore – Baltimore Sun
Late-stage trials showed that AstraZeneca’s coronavirus vaccine, which is being manufactured for the United States in Baltimore, was up to 90% effective, the English…
Read More
Maryland Company Poised to Produce Millions of Point-of-Care COVID-19 Tests that Deliver Accurate Results in 15 Minutes · BioBuzz
Rockville, Maryland’s Maxim Biomedical (MaximBio) is on the cusp of bringing 3 million of its new and effective point-of-care COVID-19 tests to the fight…
Read More
Altimmune Announces Submission of Investigational New Drug Application for AdCOVID™ a Single-dose Intranasal COVID-19 Vaccine; On Track to Commence Phase 1 Clinical Study in December Nasdaq:ALT
GAITHERSBURG, Md., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutics, today…
Read More